221 related articles for article (PubMed ID: 32683564)
1. CDH2/N-cadherin and early diagnosis of invasion in patients with ductal carcinoma in situ.
Guvakova MA; Prabakaran I; Wu Z; Hoffman DI; Huang Y; Tchou J; Zhang PJ
Breast Cancer Res Treat; 2020 Sep; 183(2):333-346. PubMed ID: 32683564
[TBL] [Abstract][Full Text] [Related]
2. Factors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ.
Takada K; Kashiwagi S; Asano Y; Goto W; Morisaki T; Takahashi K; Fujita H; Takashima T; Tomita S; Hirakawa K; Ohira M
BMC Cancer; 2020 Jun; 20(1):513. PubMed ID: 32493410
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of ductal carcinoma in situ with invasive breast cancer in core needle biopsies for final pathologic size of intraductal elements.
Matsumoto H; Ishii A; Nakada N; Koki A; Unesoko M; Abe N; Zaha H
Virchows Arch; 2022 Apr; 480(4):739-748. PubMed ID: 34993592
[TBL] [Abstract][Full Text] [Related]
4. Validation of an oligo-gene signature for the prognostic stratification of ductal carcinoma in situ (DCIS).
Geradts J; Groth J; Wu Y; Jin G
Breast Cancer Res Treat; 2016 Jun; 157(3):447-59. PubMed ID: 27250000
[TBL] [Abstract][Full Text] [Related]
5. Preoperative clinicopathologic factors and breast magnetic resonance imaging features can predict ductal carcinoma in situ with invasive components.
Lee CW; Wu HK; Lai HW; Wu WP; Chen ST; Chen DR; Chen CJ; Kuo SJ
Eur J Radiol; 2016 Apr; 85(4):780-9. PubMed ID: 26971424
[TBL] [Abstract][Full Text] [Related]
6. Is it possible to predict underestimation in ductal carcinoma in situ of the breast? Yes, using a simple score!
Marques LC; Marta GN; de Andrade JZ; Andrade D; de Barros ACSD; Andrade FEM
Eur J Surg Oncol; 2019 Jul; 45(7):1152-1155. PubMed ID: 30665684
[TBL] [Abstract][Full Text] [Related]
7. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
[TBL] [Abstract][Full Text] [Related]
8. Nomogram for predicting invasion in patients with a preoperative diagnosis of ductal carcinoma in situ of the breast.
Lee SK; Yang JH; Woo SY; Lee JE; Nam SJ
Br J Surg; 2013 Dec; 100(13):1756-63. PubMed ID: 24227361
[TBL] [Abstract][Full Text] [Related]
9. Tumor thickness and histological features as predictors of invasive foci within preoperatively diagnosed ductal carcinoma in situ.
Mori K; Takeda M; Kodama Y; Kiyokawa H; Yasojima H; Mizutani M; Otani Y; Morikawa N; Masuda N; Mano M
Hum Pathol; 2017 Jun; 64():145-155. PubMed ID: 28434924
[TBL] [Abstract][Full Text] [Related]
10. Identification of lesion subtypes in biopsies of ductal carcinoma in situ of the breast using biomarker ratio imaging microscopy.
Clark AJ; Petty HR
Sci Rep; 2016 Jun; 6():27039. PubMed ID: 27247112
[TBL] [Abstract][Full Text] [Related]
11. Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS.
Visser LL; Elshof LE; Van de Vijver K; Groen EJ; Almekinders MM; Sanders J; Bierman C; Peters D; Hofland I; Broeks A; van Leeuwen FE; Rutgers EJT; Schmidt MK; Schaapveld M; Lips EH; Wesseling J
Am J Surg Pathol; 2019 Nov; 43(11):1574-1582. PubMed ID: 31206365
[TBL] [Abstract][Full Text] [Related]
12. A nomogram for predicting underestimation of invasiveness in ductal carcinoma in situ diagnosed by preoperative needle biopsy.
Park HS; Kim HY; Park S; Kim EK; Kim SI; Park BW
Breast; 2013 Oct; 22(5):869-73. PubMed ID: 23601760
[TBL] [Abstract][Full Text] [Related]
13.
Zhang Z; Wang H; Jin Y; Zhou J; Chu C; Tang F; Zou L; Zou Q
Biomark Med; 2023 Jun; 17(12):553-562. PubMed ID: 37814985
[No Abstract] [Full Text] [Related]
14. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral metabolic heterogeneity predicts invasive components in breast ductal carcinoma in situ.
Yoon HJ; Kim Y; Kim BS
Eur Radiol; 2015 Dec; 25(12):3648-58. PubMed ID: 26063655
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation in ductal carcinoma in situ of the male breast.
Vermeulen MA; van Deurzen CHM; Doebar SC; de Leng WWJ; Martens JWM; van Diest PJ; Moelans CB
Endocr Relat Cancer; 2019 Jun; 26(6):575-584. PubMed ID: 30921768
[TBL] [Abstract][Full Text] [Related]
17. Gene Expression Differences between Ductal Carcinoma in Situ with and without Progression to Invasive Breast Cancer.
Doebar SC; Sieuwerts AM; de Weerd V; Stoop H; Martens JWM; van Deurzen CHM
Am J Pathol; 2017 Jul; 187(7):1648-1655. PubMed ID: 28634007
[TBL] [Abstract][Full Text] [Related]
18. PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.
Sakr RA; Weigelt B; Chandarlapaty S; Andrade VP; Guerini-Rocco E; Giri D; Ng CK; Cowell CF; Rosen N; Reis-Filho JS; King TA
Clin Cancer Res; 2014 May; 20(9):2326-37. PubMed ID: 24634376
[TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ.
Toss MS; Miligy IM; Haj-Ahmad R; Gorringe KL; AlKawaz A; Mittal K; Ellis IO; Green AR; Rakha EA
Histopathology; 2019 Jun; 74(7):1025-1035. PubMed ID: 30725481
[TBL] [Abstract][Full Text] [Related]
20. Predictors of residual invasive disease after core needle biopsy diagnosis of ductal carcinoma in situ.
Rutstein LA; Johnson RR; Poller WR; Dabbs D; Groblewski J; Rakitt T; Tsung A; Kirchner T; Sumkin J; Keenan D; Soran A; Ahrendt G; Falk JS
Breast J; 2007; 13(3):251-7. PubMed ID: 17461899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
